Activity Details

0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: August 8, 2018
Expires: August 7, 2019
30 minutes to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for medical oncologists, thoracic oncologists, pulmonologists, pathologists, oncology nurses, and other healthcare professionals involved in the treatment of NSCLC.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Analyze treatment options for patients with advanced NSCLC that does not have an actionable mutation target and has progressed on or after prior platinum-based therapy
  • Develop treatment plans for patients with advanced NSCLC without targetable activating mutations that has progressed on or after prior platinum-based therapy according to clinical practice guidelines
  • Select appropriate treatment for NSCLC without targetable activating mutations that has progressed rapidly on initial platinum-based therapy

Activity Description

Lung cancer continues to be the leading cause of cancer death in the United States, accounting for 27% of all cancer deaths in males and 25% in females. Non–small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases. The prognosis of patients with NSCLC is poor; the 5-year overall survival (OS) rate is 5% for those with metastatic disease and 18% across all stages. Approximately 70% of patients with lung cancer have advanced or metastatic disease at initial diagnosis.

The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF mutations has led to an improvement in OS and progression-free survival by identifying subgroups of patients who benefit from targeted treatment. “Although recent advances have improved clinical outcomes for patients with tumors harboring targetable driver mutations, most NSCLC tumors lack these mutations, highlighting the need for novel therapeutic interventions… Patients with advanced NSCLC that is aggressive and rapidly progresses after first-line treatment have a poor prognosis and have been studied in several trials” (Reck et al, 2017).

This activity will review available treatment options, current guideline recommendations, and recent data about disease that has progressed rapidly on initial therapy to inform appropriate treatment selection.

Statement of Educational Need

The goal of this activity is to provide clinicians with the latest advances in the treatment of patients with advanced NSCLC without targetable activating mutations that has progressed on prior platinum-based therapy, including patients with disease that has progressed rapidly on initial therapy.


Stephen V. Liu, MD
Associate Professor of Medicine
Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, DC

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Stephen V. Liu, MD, reported a financial interest/relationship or affiliation in the form of Advisor/Consultant, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co, Celgene Corp, Genentech/Roche, Ignyta, Lilly USA, Pfizer, Inc, Taiho Pharmaceutical Co, Ltd, Takeda Oncology; Contracted research, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Corvus Pharmaceuticals, Esanex Inc, Genentech, Inc, Ignyta, Lycera, MedImmune, Merck & Co, Inc, OncoMed Pharmaceuticals, Pfizer, Inc, Threshold Pharmaceuticals.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn Haas, PhD, RN, CNS, ANP-BC; and Stephanie Sutphin, PharmD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 100% and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.